ArticleFrontiers in oncology2026
Case Report: Complete response to the novel NaPi2b-targeting ADC YL205 in heavily pretreated platinum-resistant ovarian cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: High-grade serous ovarian carcinoma (HGSOC) remains a formidable challenge in the platinum-resistant setting (PROC). In the post-PARP inhibitor (PARPi) era, prior exposure reshapes resistance mechanisms, necessitating a shift from traditional platinum-free interval definitions to biomarker-driven strategies. We report an exceptional response to a next-generation ADC and review the evolving therapeutic landscape. Case report: A 40-year-old woman with FIGO stage IVB, BRCA-wildtype HGSOC developed rapid multi-drug resistance following neoadjuvant chemotherapy, optimal cytoreduction, and progression on maintenance olaparib/bevacizumab, gemcitabine, and a USP1 inhibitor. Following the identification of high NaPi2b expression (83% tumor proportion score), she initiated YL205, a novel NaPi2b-targeting antibody-drug conjugate (ADC) utilizing a topoisomerase I inhibitor payload, at 2.0 mg/kg every 3 weeks. Results: The patient achieved a sustained complete radiological response (CR) and CA-125 normalization 3.5U/ml after 24 weeks, remaining stable through 48 weeks treatment. This represents the first clinical instance of CR observed with this agent. Adverse events were limited to manageable grade 1-2 neutropenia symptoms. Conclusions: This case underscores the potential of next-generation ADCs featuring optimized linker-payload technologies. By utilizing topoisomerase I inhibitors, agents like YL205 bypass microtubule-stabilization resistance induced by prior taxane exposure, while "bystander effects" address intratumoral heterogeneity. Longitudinal, biomarker-matched strategies and proactive toxicity management are essential to achieving deep tissue clearance in heavily pretreated HGSOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.